 Aptose Biosciences Inc. Aptose or the Company NASDAQ: APTO, TSX: APS, a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, today announced that it has entered into an equity distribution agreement the Equity Distribution Agreement with Piper Sandler and Canaccord Genuity collectively Agents. Under the terms of the Equity Distribution Agreement, the Company may, from time to time, issue and sell through the Agents, common shares of the Company the Common Shares through at-the-market ATM distributions the Offering on the Nasdaq Capital Market NASDAQ. 